Patents and Trademarks
Refine search
Biotechnology
US clinical-stage biopharma Arbutus Biopharma saw its shares rise 4% to $4.70 in premarket activity today, as it announced initiation of patent infringement action. 16 July 2026
Biotechnology
The 2026 BIO International Convention brought together biotech leaders, policymakers, patients, and innovators to discuss the industry's biggest opportunities and challenges. 6 July 2026
Pharmaceutical
The Russian Supreme Court has refused to review the dispute of UK pharma major AstraZeneca with the Russian drugmaker Akrikhin dispute over Forxiga (dapagliflozin) - a drug for the treatment of type 2 diabetes – that became a response to the cassation appeal, which was earlier filed by AstraZeneca. 6 July 2026
Generics
The Russian Patent and Trademark Office refused to overturn the patent for the anticoagulant apixaban, which is owned by US pharma major Bristol Myers Squibb on the basis of the claim filed by the Israeli pharmaceutical company Teva Pharmaceutical Industries, reports The Pharma Letter’s local correspondent. 25 June 2026
Pharmaceutical
The Boston, USA-based unit of French nuclear medicines firm Curium today announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium concerning its Lutetium Lu 177 dotatate product. 18 June 2026
Pharmaceutical
Russia may revise the patent protection terms for drugs with aim to reduce their length from the current 25 years to 15-20 years or even lower. 16 June 2026
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has urged EU lawmakers to widen a proposed patent-style incentive in the Biotech Act, warning that the current plan is too narrow to materially shift investment decisions. 15 June 2026
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Pharmaceutical
Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in pharmaceutical history. 14 May 2026
Pharmaceutical
India has once again been placed on the Priority Watch List in the 2026 Special 301 Report released by the Office of the United States Trade Representative (USTR). 13 May 2026
Generics
US pharma giant Pfizer yesterday announced that it has entered into settlement agreements with generic drug manufacturers - Dexcel Pharma, Hikma Pharmaceuticals and Cipla - regarding lawsuits filed in the US District Court for the District of Delaware for infringement of patents relating to Vyndamax (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). 29 April 2026
Pharmaceutical
As Europe strives to compete globally in life sciences, predictable and robust IP incentives will determine whether tomorrow’s breakthroughs are developed here or elsewhere, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). 27 April 2026
Generics
Axelpharm, the Russian manufacturer of anticancer generics, may suspend operations due to fines from the local antitrust regulator the Federal Antimonopoly Service (FAS), which were imposed for the company’s participation in patent disputes. 21 April 2026
Biosimilars
Israeli drugmaker Teva has regained the upper hand in its long-running migraine patent dispute with US pharma major Eli Lilly, after a federal appeals court reinstated a $176.5 million jury award tied to rival drugs Ajovy (fremanezumab) and Emgality (galcanezumab). 20 April 2026
Generics
India’s generics industry appears to be reshaping the weight loss and diabetes drug market, with Eli Lilly’s share in the GLP-1 category slipping sharply in March. 14 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
The US House of Representatives submitted questions regarding a relatively unknown but very important European legislative proposal: the EU Biotech Act. 7 April 2026
Generics
India has moved ahead in developing indigenous capacity for cell and gene therapies, with regulatory bodies issuing national guidelines to ensure safe and ethical deployment of CRISPR-based technologies. 3 April 2026
Pharmaceutical
With unprecedented patent cliffs looming, putting an estimated $200 to $400 billion in annual global sales at risk, senior strategy consultant and Nmblr founder, Janice MacLennan, is issuing a stark warning to biopharma organizations tasked with delivering innovative new therapies to market. 1 April 2026
Biotechnology
US clinical-stage biopharma Arbutus Biopharma saw its shares rise 4% to $4.70 in premarket activity today, as it announced initiation of patent infringement action. 16 July 2026
Biotechnology
The 2026 BIO International Convention brought together biotech leaders, policymakers, patients, and innovators to discuss the industry's biggest opportunities and challenges. 6 July 2026
Pharmaceutical
The Russian Supreme Court has refused to review the dispute of UK pharma major AstraZeneca with the Russian drugmaker Akrikhin dispute over Forxiga (dapagliflozin) - a drug for the treatment of type 2 diabetes – that became a response to the cassation appeal, which was earlier filed by AstraZeneca. 6 July 2026
Generics
The Russian Patent and Trademark Office refused to overturn the patent for the anticoagulant apixaban, which is owned by US pharma major Bristol Myers Squibb on the basis of the claim filed by the Israeli pharmaceutical company Teva Pharmaceutical Industries, reports The Pharma Letter’s local correspondent. 25 June 2026
Pharmaceutical
The Boston, USA-based unit of French nuclear medicines firm Curium today announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium concerning its Lutetium Lu 177 dotatate product. 18 June 2026
Pharmaceutical
Russia may revise the patent protection terms for drugs with aim to reduce their length from the current 25 years to 15-20 years or even lower. 16 June 2026
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has urged EU lawmakers to widen a proposed patent-style incentive in the Biotech Act, warning that the current plan is too narrow to materially shift investment decisions. 15 June 2026
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Pharmaceutical
Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in pharmaceutical history. 14 May 2026
Pharmaceutical
India has once again been placed on the Priority Watch List in the 2026 Special 301 Report released by the Office of the United States Trade Representative (USTR). 13 May 2026
Generics
US pharma giant Pfizer yesterday announced that it has entered into settlement agreements with generic drug manufacturers - Dexcel Pharma, Hikma Pharmaceuticals and Cipla - regarding lawsuits filed in the US District Court for the District of Delaware for infringement of patents relating to Vyndamax (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). 29 April 2026
Pharmaceutical
As Europe strives to compete globally in life sciences, predictable and robust IP incentives will determine whether tomorrow’s breakthroughs are developed here or elsewhere, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). 27 April 2026
Generics
Axelpharm, the Russian manufacturer of anticancer generics, may suspend operations due to fines from the local antitrust regulator the Federal Antimonopoly Service (FAS), which were imposed for the company’s participation in patent disputes. 21 April 2026
Biosimilars
Israeli drugmaker Teva has regained the upper hand in its long-running migraine patent dispute with US pharma major Eli Lilly, after a federal appeals court reinstated a $176.5 million jury award tied to rival drugs Ajovy (fremanezumab) and Emgality (galcanezumab). 20 April 2026
Generics
India’s generics industry appears to be reshaping the weight loss and diabetes drug market, with Eli Lilly’s share in the GLP-1 category slipping sharply in March. 14 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
The US House of Representatives submitted questions regarding a relatively unknown but very important European legislative proposal: the EU Biotech Act. 7 April 2026
Generics
India has moved ahead in developing indigenous capacity for cell and gene therapies, with regulatory bodies issuing national guidelines to ensure safe and ethical deployment of CRISPR-based technologies. 3 April 2026
Pharmaceutical
With unprecedented patent cliffs looming, putting an estimated $200 to $400 billion in annual global sales at risk, senior strategy consultant and Nmblr founder, Janice MacLennan, is issuing a stark warning to biopharma organizations tasked with delivering innovative new therapies to market. 1 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze